Bolt Biotherapeutics Inc, a private biotechnology company that says it is focused on unleashing the power of the immune system to treat cancer, announced yesterday that it has named Randall Schatzman as its new chief executive officer and as its new director.

Dr Schatzman brings more than 30 years of biotech leadership experience to the company and most recently served as president and CEO of Alder BioPharmaceuticals Inc.

Peter Moldt, of Novo Ventures and executive chairman of the board of Bolt Biotherapeutics, said, 'I am very pleased to welcome Randy as our chief executive officer. We believe our ISAC technology has great potential and look forward to Randy's expert leadership to successfully advance Bolt's programs and therapeutic candidates.'